Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | IDUA | P35475 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850007 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL18030805 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL13523545 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL24212702 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL7152405 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL23343942 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL13478949 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL21134565 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL21586585 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL14208597 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200147229-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10596270-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-03-21 | — | — | US | disclosed |
| WO-2019023316-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR2, FOLR1, FCGRT | FGF2 974/4885M6PR 736/4885AKT1 4348/4885 |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | FGF2 410/4885M6PR 4726/4885AKT1 2112/4885 |
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | FGF2 1603/4885M6PR 153/4885AKT1 3524/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | FGF2 641/4885M6PR 1156/4885AKT1 3662/4885 |
| US-10596270-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | FOLR1, FOLR2, DHFR | FGF2 1961/4885M6PR 110/4885AKT1 4012/4885 |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | FGF2 1961/4885M6PR 110/4885AKT1 4012/4885 |
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | CD74, CD99, CD2 | FGF2 4364/4885M6PR 2495/4885AKT1 4145/4885 |
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | FGF2 675/4885M6PR 1159/4885AKT1 3431/4885 |
| US-20200147229-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | FGF2 1961/4885M6PR 110/4885AKT1 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.